Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-06-16
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 530317, 530328, A61K 3812, A61K 3800, C07K 700, C07K 750
Patent
active
057670714
ABSTRACT:
The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. These peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as osteoporosis, restenosis, and angiogenic-based diseases, including cancer, arthritis, and diabetic retinopathy.
REFERENCES:
patent: 4271068 (1981-06-01), Kamber et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4988621 (1991-01-01), Ruoslahti et al.
patent: 5262520 (1993-11-01), Plow et al.
STN search results
Brooks et al., "Requirement of Vascular Integrin .alpha..sub.v .beta..sub.3 for Angiogenesis" Science, vol. 264, pp. 569-571 (1994).
Brooks et al., "Integrin .alpha..sub.v .beta..sub.3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels" Cell, vol. 79, pp. 1157-1164 (1994).
Nicosia and Bonanno, "Inhibition of Angiogenesis In Vitro by Arg-Gly-Asp-Containing Synthetic Peptide" Amer. J. Path., vol. 138, pp. 829-833.
Choi et al., "Inhibition of Neointimal Hyperplasia by Blocking .alpha..sub.v .beta..sub.3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA" J. Vasc. Surg., vol. 19, pp. 125-134 (1994).
Matusno et al., "Inhibition of Integrin Function by a Cyclic RGD-Containing Peptide Prevents Neointima Formation" Circ. 90, pp. 2203-2206 (1994).
Miyauchi et al., "Recognition of Osteopontin and Related Peptides by an .alpha..sub.v .beta..sub.3 Integrin Stimulates Immediate Cell Signals in Osteoclasts" J. Biol. Chem., vol. 266, pp. 20369-20374.
Sato et al., "Echistatin Is a Potent Inhibitor of Bone Resorption in Culture" J. Cell. Biol., vol. 111, pp. 1713-1723 (1990).
Ross et al., "Interactions Between the Bone Matrix Proteins Osteopontin and Bone Sialoprotein and the Osteoclast Integrin .alpha..sub.v .beta..sub.3 Potentiate Bone Resorption" J. Biol. Chem., vol. 268, pp. 9901-9907 (1993).
Horton et al., "Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23C6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts" Exp. Cell Res., vol. 195, pp. 368-375 (1991).
Liaw et al., "The Adhesive and Migratory Effects of Osteopontin Are Mediated via Distinct Cell Surface Integrins" J. Clin. Invest., vol. 95, pp. 713-724 (1995).
Pierschbacher and Ruoslahti, "Variants of the Cell Recognition Site of Fibronectin that Retain Attachment-Promoting Activity" Proc. Natl. Acad. Sci., vol. 81, pp. 5985-5988 (1984).
Ruoslahti and Pierschbacher, "Arg-Gly-Asp: A Versatile Cell Recognition Signal" Cell, vol. 44, pp. 517-518 (1986).
Smith et al., Interaction of Integrins .alpha..sub.v .beta..sub.3 and Glycoprotein IIb-IIIa with Fibrinogen J. Biol. Chem., vol. 265, pp. 12267-12271 (1990).
Ruoslahti and Pierschbacher, "New Perspectives in Cell Adhesion: RGD and Integrins" Science, vol. 238, pp. 491-497 (1987).
Humphries, "The Molecular Basis and Specificity of Integrin-Ligand Interactions" J. Cell Sci., vol. 97, pp. 585-592 (1990).
Ruoslahti, "Integrins" J. Clin. Invest., vol. 87, pp. 1-5 (1991).
Pierschbacher and Ruoslahti, "Influence of Stereochemistry of the Sequence Arg-Gly-Asp-Xaa on Binding Specificity in Cell Adhesion" J. Bio. Chem., vol. 262, pp. 17924-17928 (1987).
Aumailley et al., "Arg-Gly-Asp Constrained Within Cyclic Pentapeptides" FEBS, vol. 291, pp. 50-54 (1991).
Koivunen et al., "Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins" Biotech., vol. 13, pp. 265-270 (1995).
Obara et al., "Site-Directed Mutagenesis of the Cell-Binding Domain of Human Fibronectin: Separable, Synergistic Sites Mediate Adhesive Function" Cell, 53, pp. 649-657 (1988).
Beacham et al., "Selective Inactivation of the Arg-Gly-Asp-Ser (RGDS) Binding site in von Willebrand Factor by Site-Directed Mutagenesis" J. Biol. Chem., vol. 267, pp. 3409-3415 (1992).
Cherny et al., "Site-Directed Muta-Genesis of the Arginine-Glycine-Aspartic Acid in Vitronectin Abolishes Cell Adhesion" J. Biol. Chem., vol. 268, pp. 9725-9729 (1993).
Cheresh, "Integrins: Structure, Function, and Biological Properties" Advances in Molecular and Cell Biology, vol. 6, pp. 225-252 (1993).
Luscinskas and Lawler, "Integrins as Dynamic Regulators of Vascular Function" The FASEB Journal, vol. 8, pp. 929-938 (1994).
Nowlin et al., "A Novel Cyclic Pentapeptide Inhibits .alpha.4.beta.1 and .alpha.5.beta.1 Integrin-Mediated Cell Adhesion" The Journal of Biological Chemistry, vol. 27, pp. 20352-20359 (1993).
Koivunen et al., "Selection of Peptides Binding to the .alpha..sub.5 .beta..sub.1 Integrin from Phage Display Library" The Journal of Biological Chemistry, vol. 27, pp. 20205-20210 (1993).
Koivunen et al., "Isolation of a Highly Specific Ligand for the .alpha..sub.5 .beta..sub.1 Integrin from a Phage Display Library" The Journal of Cell Biology, vol. 124, pp. 373-380 (1994).
Scarborough et al., "Barbourin" The Journal of Biological Chemistry, vol. 266, pp. 9359-9362 (1991).
McDowell and Gadek, "Structural Studies of Potent Constrained RGD Peptides" Journal of the American Chemical Society, vol. 114, pp. 9245-9253 (1992).
Barker et al., "Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics" Journal of Medicinal Chemistry, vol. 35, pp. 2040-2048 (1992).
Nip et al., (1992) "Human Melanoma Cells Derived From Lymphatic Metastases Use Integrin .alpha..sub.v .beta..sub.3 to Adhere to Lymph Node Vitronectin" J. Clin. Invest. 90:1406-1413.
Pfaff et al., (1994) "Selective Recognition of Cyclic RGD Peptides of NMR Defeined Conformation by .alpha.IIb.beta.3, .alpha.V.beta.3, and .alpha.5.beta.1 Integrins" J. Biol. Chem. 269(32):20233-20238.
Leven et al., (1992) "Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro Is Mediated Through the Vitronectin Receptor" Exp. Hematol. 20:1316-1322.
Horton et al., (1993) "Modulation of Vitronectin Receptor-Mediated Osteoclast Adhesion by Arg-Gly-Asp Peptide Analogs: A Structure-Function Analysis" Journal of Bone and Mineral Research 8(2):239-247.
Huse William D.
Lee Bruce A.
Palladino Michael A.
Varner Judith A.
Borin Michael
IXSYS Incorporated
Tsang Cecilia J.
LandOfFree
Sevenmer cyclic peptide inhibitors of diseases involving .alpha. does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sevenmer cyclic peptide inhibitors of diseases involving .alpha., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sevenmer cyclic peptide inhibitors of diseases involving .alpha. will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726028